An Lp(a) of 150 nmol/L is elevated. The landmark most guidelines use is 125 nmol/L, or 50 mg/dL if your lab reports in mass units. The two scales do not convert with a universal multiplier, because the size of the apo(a) particle varies from person to person, so read the unit before you read the number, and prefer the nmol/L result when your laboratory reports one.
Here is what makes this number different from every other one on a lipid panel: it is mostly inherited, it is stable across a lifetime for most people, and diet and exercise usually do not lower it meaningfully. So the useful response is not to try to fix the number. It is to do two other things, and the second one is about people who are not you.
What it is
Lipoprotein(a) is an LDL-like particle with an extra protein, apolipoprotein(a), bound to it. Higher levels are associated with heart attack and stroke, and the genetic evidence says the link is causal: people who inherit the variants that raise Lp(a) have more heart attacks. High Lp(a) is also associated with calcific aortic valve stenosis, the stiffening of the valve that leaves the heart, which is another reason I treat it as a meaningful lifetime risk marker. In one genetic study, each copy of the common LPA risk variant carried twice the odds of valve calcification and about 1.7 times the rate of aortic stenosis. A role in clotting has been shown in the laboratory and not established in patients.
The level is set largely by one gene, LPA, and family studies put the heritability near 90 percent. The European guidelines have said since 2019 to measure it at least once in every adult's lifetime, and the 2026 American multisociety guideline now says the same. For most adults, one good measurement is enough. I repeat it when there is a reason to think the biological or measurement context has changed: kidney or liver disease, an underactive thyroid, pregnancy, acute illness, or hormone therapy after menopause, which lowers it. Otherwise there is nothing to track.
Roughly one in five people carries an elevated level, most without knowing it, because it is not on a standard cholesterol panel and has to be requested. A person with an Lp(a) of 150 can have an entirely unremarkable lipid panel: the relative who ate well, ran regularly, had normal cholesterol, and had a heart attack at fifty-two. Elevated Lp(a) is not the only explanation for that story, but it is one worth ruling out, inexpensive to check and still often unchecked.
The first response: lower everything else, further
Lp(a) does not create a treatment on its own. It changes the weight of everything else. The American guidelines treat an Lp(a) at or above 125 nmol/L as a risk-enhancing factor. An elevated Lp(a) pushes me toward more intensive control of LDL cholesterol and the rest of cardiovascular risk, with the actual target determined by your overall risk rather than by the Lp(a) number itself.
I often look at ApoB as another measure of atherogenic particle burden, and each Lp(a) particle carries one apoB, so it is part of what that count includes. Its target depends on the rest of the risk picture rather than on the Lp(a) result. Blood pressure, diabetes, smoking and the other modifiable cardiovascular risk factors are managed in the context of the person's overall risk.
In two American cohorts, people with high Lp(a) and a coronary calcium score of 100 or more had cardiovascular event rates above 20 percent over follow-up; with the same Lp(a) and a score under 100, under 10 percent. The rest of the picture materially changes what an elevated Lp(a) means in absolute terms.
One practical caution: statins do not meaningfully lower Lp(a), and some studies show a small rise. That is not a reason to avoid a statin when one is otherwise indicated. Statins lower LDL-related cardiovascular risk, which matters even more when Lp(a) is high, and an elevated Lp(a) keeps some risk even at a lower achieved LDL. It is also a reason not to recheck your Lp(a) after starting one and be alarmed. PCSK9 inhibitors lower Lp(a) by roughly a quarter, but they lower LDL far more, and no trial has shown that the Lp(a) part of that is what helps.
The second response: this is a family finding
Because Lp(a) is largely inherited, I usually recommend that parents, siblings and adult children know their level too.
The National Lipid Association and the 2026 American guideline both say an elevated result should prompt testing of first-degree relatives. One blood test on you is a strong argument for one on each of them, and the result is durable. A twenty-six-year-old who learns their Lp(a) is 180 has forty years to act on it.
What clarifies a 150
What clarifies a 150 is the rest of the risk picture, not more Lp(a). The standard assessment comes first: age, blood pressure, diabetes, smoking, family history and the lipid panel. ApoB can add information about atherogenic particle burden in selected patients, and hs-CRP can provide another risk-enhancing factor when it would change the decision.
Then a conversation about imaging. In the right person a coronary calcium score answers a question the blood work cannot: whether the process has already started. It is endorsed for refining a decision at intermediate risk and stratifies risk independently of Lp(a). I do not order scans because they sound thorough; when an elevated Lp(a) sits alongside other risk, imaging changes what I do.
What is settled, and what just changed
For years the honest line on drugs was that therapies built to lower Lp(a) were in late-stage trials, and whether they prevent cardiovascular events was the question. The first topline answer arrived on September 4, 2026: pelacarsen lowered Lp(a), but Lp(a)HORIZON did not meet its primary cardiovascular outcome endpoint. Lp(a)HORIZON randomised 8,323 people with established cardiovascular disease and an Lp(a) of 70 mg/dL or higher to pelacarsen or placebo. The drug lowered Lp(a). It did not reduce the combined rate of cardiovascular death, heart attack, stroke and urgent revascularization. That is a topline press release, not a published paper; the full data are due at a medical congress, and I will not speculate about why it missed until they are public.
This is an important distinction in preventive medicine: a biomarker can be strongly associated with disease, and even causally related to it, without every way of lowering that biomarker necessarily improving outcomes. The first large Lp(a)-lowering outcomes trial has now reinforced that lesson.
What it does not erase is the genetic and epidemiological evidence that elevated Lp(a) is a causal cardiovascular risk factor. That evidence has not changed. What has changed is the treatment hypothesis, which turns out to be more complicated than lowering the number and expecting the events to follow.
Other trials are still worth watching for the same reason. Olpasiran produced very large reductions in Lp(a) in a phase 2 trial of 281 people with established disease, and its outcomes trial has not reported. As of September 2026, no Lp(a)-specific drug has demonstrated cardiovascular outcome benefit or received FDA approval. Lipoprotein apheresis, a filtering procedure, is a specialized option for selected very-high-risk patients with progressive disease, and indications and access vary by jurisdiction; it is not a treatment for an otherwise well person with an Lp(a) of 150.
What none of this changes is the case for measuring, which never rested on a drug. It rests on knowing your risk, treating everything else harder, and testing your family, all of which the guidelines recommended before any Lp(a) drug existed. What it does change is a line the earlier version of this essay made: that knowing your number means you are already identified when a therapy arrives. I no longer know that one is arriving. Measure it anyway.
The point
Most numbers on a lab report are a snapshot of how you are living. This one is mostly a fact about how you were built. So the question a 150 raises is a fair one: I cannot really lower it, so why did we measure it, and what do I do now?
Because it changes how seriously I manage the risks that can be changed. That remains true after HORIZON. You usually measure it once, you adjust everything else around it, and then you make sure the people who share your genes know their own number. That last step is the one that gets skipped, and it is the one with the most life in it.
If you have a lipid panel and no Lp(a) on it, that is one of the first gaps I look for. Reading results nobody has read is what the Precision Health Assessment is for.
